SBMC is part of RegMed XB, a network of four initiatives that together form the Dutch national RG pilot plant for regenerative medicine.

In Leiden, NecstGen is working on new cell and gene therapies. UMC Utrecht is responsible for the development of micro-tissues and in Maastricht ReGen Biomedical provides macro-tissues that are needed for the development of personalized regenerative therapies. SBMC manages a development facility on the Eindhoven University of Technology campus and a facility for pilot production. Our pilot factory for regenerative medicine is being built as part of the growth fund program RegMed XB.